Table 1. In Vivo Antimalarial Activity of FAQ–Pyrimidine Hybrids in the P. berghei-mouse Malaria Model.
| % parasitemia
suppressiona |
||||||
|---|---|---|---|---|---|---|
| treatment | dose (mg/kg x no. of days postinfection) | day 5 | day 7 | survivalb | MSTc | cured |
| vehicle | NA x 3 | - | - | 0/5 | 13.2 | 0/5 |
| CQ1 | 33.3 × 3 | 100.0 | 100.0 | 5/5 | 28 | 1/5 |
| CQ1 | 11.1 × 3 | 100.0 | 99.2 | 5/5 | 28 | 0/5 |
| AQ1 | 33.3 × 3 | 100.0 | 100.0 | 5/5 | 28 | 5/5 |
| AQ1 | 11.1 × 3 | 100.0 | 100.0 | 5/5 | 28 | 4/5 |
| 7f2 | 33.3 × 3 | 100.0 | 100.0 | 5/5 | 28 | 3/5 |
| 7f2 | 11.1 × 3 | 91.9 | 92.9 | 2/5 | 19.8 | 0/5 |
| 8b2 | 33.3 × 3 | 100.0 | 100.0 | 5/5 | 28 | 5/5 |
| 8b2 | 11.1 × 3 | 100.0 | 100.0 | 5/5 | 28 | 0/5 |
a
The % suppression in parasitemia is calculated by considering the mean parasitemia in the vehicle control as 100%. Parasitemia suppression <80% is considered as nonsignificant.
b
Number of animals that survived on day 28/total animals in the group (the day of the death postinfection).
c
MST, mean survival time (days).
d
Number of mice without parasitemia (cured) until day 28 postinfection;1 oral-administration; 2intraperitoneal-administration